Why bother using non-human primate models of cognitive disorders in translational research?

Neurobiology of Learning and Memory

Volumn 124, Issue , 2015, Pages 123-129

  Camus, Sandrine ^a   Ko, Wai Kin D ^a   Pioli, Elsa ^a   Bezard, Erwan ^a,b  

^a Williams House   (United Kingdom)

^b INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

Author keywords

Alzheimer; Cantab; Depression; Ethology; Non human primate; Parkinson; Transgenesis

Indexed keywords

DIMEBON; LEVODOPA;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DEPRESSION; DNA MODIFICATION; DRUG EFFECT; HUMAN; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; MOOD DISORDER; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIMATE MODEL; REVIEW; SPATIAL MEMORY; TRANSLATIONAL RESEARCH; ANIMAL; BRAIN; DISEASE MODEL; GENETICS; MACACA; PRIMATE; PROCEDURES; SPECIES DIFFERENCE;

ALZHEIMER DISEASE; ANIMALS; BRAIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; MACACA; PARKINSON DISEASE; PRIMATES; SPECIES SPECIFICITY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84941259954     PISSN: 10747427     EISSN: 10959564     Source Type: Journal    
DOI: 10.1016/j.nlm.2015.06.012     Document Type: Review

References (144)

1. Altmann J. Observational study of behavior: Sampling methods. Behaviour 1974, 49(3):227-267.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Press, Washington, DC.
3. Apicella P., Ljungberg T., Scarnati E., Schultz W. Responses to reward in monkey dorsal and ventral striatum. Experimental Brain Research 1991, 85(3):491-500.
4. Aron Badin R., Caillierez R., Colin M., Bemelmans A., Dufour N., et al. Characterization of a novel non-human primate model of tauopathy. Society for neuroscience 2014, Poster, Washington, DC.
5. Bebarta V., Luyten D., Heard K. Emergency medicine animal research: Does use of randomization and blinding affect the results?. Academic Emergency Medicine 2003, 10(6):684-687.
6. Belzung C., Lemoine M. Criteria of validity for animal models of psychiatric disorders: Focus on anxiety disorders and depression. Biology Mood Anxiety Disord 2011, 1(1):9.
7. Benazzouz A., Gross C., Feger J., Boraud T., Bioulac B. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. European Journal of Neuroscience 1993, 5(4):382-389.
8. Berton O., Hahn C.G., Thase M.E. Are we getting closer to valid translational models for major depression?. Science 2012, 338(6103):75-79.
9. Billings L.M., Oddo S., Green K.N., McGaugh J.L., LaFerla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005, 45(5):675-688.
10. Bowlby J. Grief and mourning in infancy and early childhood. Psychoanalytic Study of the Child 1960, 15:9-52.
11. Brown R.G., Marsden C.D. Internal versus external cues and the control of attention in Parkinson's disease. Brain 1988, 111(Pt 2):323-345.
12. Brune M., Brune-Cohrs U., McGrew W.C., Preuschoft S. Psychopathology in great apes: Concepts, treatment options and possible homologies to human psychiatric disorders. Neuroscience and Biobehavioral Reviews 2006, 30(8):1246-1259.
13. Buerger K., Ewers M., Pirttila T., Zinkowski R., Alafuzoff I., Teipel S.J., et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006, 129(Pt 11):3035-3041.
14. Button K.S., Ioannidis J.P., Mokrysz C., Nosek B.A., Flint J., Robinson E.S., et al. Power failure: Why small sample size undermines the reliability of neuroscience. Nature Reviews Neuroscience 2013, 14(5):365-376.
15. Camus S.M., Blois-Heulin C., Li Q., Hausberger M., Bezard E. Behavioural profiles in captive-bred cynomolgus macaques: Towards monkey models of mental disorders?. PLoS ONE 2013, 8(4):e62141.
16. Camus S.M., Rochais C., Blois-Heulin C., Li Q., Hausberger M., Bezard E. Birth origin differentially affects depressive-like behaviours: Are captive-born cynomolgus monkeys more vulnerable to depression than their wild-born counterparts?. PLoS ONE 2013, 8(7):e67711.
17. Camus S.M., Rochais C., Blois-Heulin C., Li Q., Hausberger M., Bezard E. Depressive-like behavioural profiles in captive-bred single- and socially-housed rhesus and cynomolgus macaques: A species comparison. Frontiers in Behavioral Neuroscience 2014, 8:10.
18. Capitanio J.P., Emborg M.E. Contributions of non-human primates to neuroscience research. Lancet 2008, 371(9618):1126-1135.
19. Chemical Heritage Foundation. Preventing and treating infectious diseases: Jonas Salk and Albert Bruce Sabin. http://www.chemheritage.org/discover/online-resources/chemistry-in-history/themes/pharmaceuticals/preventing-and-treating-infectious-diseases/salk-and-sabin.aspx.
20. Chen G., Chen K.S., Knox J., Inglis J., Bernard A., Martin S.J., et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000, 408(6815):975-979.
21. Chrousos G.P. Stress and disorders of the stress system. Nature Reviews Endocrinology 2009, 5(7):374-381.
22. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neuroscience Biobehaviour Reviews 2006, 30(1):1-23.
23. Cooper J.A., Sagar H.J., Doherty S.M., Jordan N., Tidswell P., Sullivan E.V. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain 1992, 115(Pt 6):1701-1725.
24. Courtine G., Roy R.R., Raven J., Hodgson J., McKay H., Yang H., et al. Performance of locomotion and foot grasping following a unilateral thoracic corticospinal tract lesion in monkeys (Macaca mulatta). Brain 2005, 128(Pt 10):2338-2358.
25. Crawley J.N. Behavioral phenotyping strategies for mutant mice. Neuron 2008, 57(6):809-818.
26. de Waal F.B., Bonnie K.E. In tune with others: The social side of primate culture. The question of animal culture 2009, 19-39. Harvard University Press, Cambridge. K.N. Laland, B.G. Galef (Eds.).
27. de Waal F.B., Johanowicz D.L. Modification of reconciliation behavior through social experience: An experiment with two macaque species. Child Development 1993, 64(3):897-908.
28. Dehay B., Dalkara D., Dovero S., Li Q., Bezard E. Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques. Scientific Reports 2012, 2:253.
29. Delatour B., Guegan M., Volk A., Dhenain M. In vivo MRI and histological evaluation of brain atrophy in APP/PS1 transgenic mice. Neurobiology Aging 2006, 27(6):835-847.
30. Deussing J.M. Animal models of depression. Drug Discovery Today: Disease Models 2006, 3(4):375-383.
31. Diamond A. Evidence for the importance of dopamine for prefrontal cortex functions early in life. Philosophical Transactions Royal Society London B Biology Science 1996, 351(1346):1483-1493. discussion 1494.
32. DiLuca M., Olesen J. The cost of brain diseases: A burden or a challenge?. Neuron 2014, 82(6):1205-1208.
33. Doody R.S., Gavrilova S.I., Sano M., Thomas R.G., Aisen P.S., Bachurin S.O., et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: A randomised, double-blind, placebo-controlled study. Lancet 2008, 372(9634):207-215.
34. Dovero S., Bourdenx M., Bastide M., Bido S., Engeln M., Piron C., et al. Progressive nigrostriatal neurodegeneration associated with α-synuclein spreading and pathology induced by AAV-mediated overexpression of mutant α-synuclein in mice, rats and marmosets Society for Neuroscience 2014, Poster, Washington, DC.
35. Downes J.J., Roberts A.C., Sahakian B.J., Evenden J.L., Morris R.G., Robbins T.W. Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: Evidence for a specific attentional dysfunction. Neuropsychologia 1989, 27(11-12):1329-1343.
36. Ferdowsian H.R., Durham D.L., Kimwele C., Kranendonk G., Otali E., Akugizibwe T., et al. Signs of mood and anxiety disorders in chimpanzees. PLoS ONE 2011, 6(6):e19855.
37. Fernagut P.O., Li Q., Dovero S., Chan P., Wu T., Ravenscroft P., et al. Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys. PLoS ONE 2010, 5(11):e14053.
38. Fisch G.S. Animal models and human neuropsychiatric disorders. Behavior Genetics 2007, 37(1):1-10.
39. Flowers K.A., Robertson C. The effect of Parkinson's disease on the ability to maintain a mental set. Journal of Neurology, Neurosurgery and Psychiatry 1985, 48(6):517-529.
40. Fooden J. Comparative review of fascicularis-group species of macaques (primates: Macaca). Fieldiana Zoology 2006, 1-43.
41. Fox S.H., Johnston T.H., Li Q., Brotchie J., Bezard E. A critique of available scales and presentation of the non-human primate dyskinesia rating scale. Movement Disorders 2012, 27(11):1373-1378.
42. Fureix C., Jego P., Henry S., Lansade L., Hausberger M. Towards an ethological animal model of depression? A study on horses. PLoS ONE 2012, 7(6):e39280.
43. Geerts E., Brune M. Ethological approaches to psychiatric disorders: Focus on depression and schizophrenia. Australian and New Zealand Journal of Psychiatry 2009, 43(11):1007-1015.
44. Gibbs R.A., Rogers J., Katze M.G., Bumgarner R., Weinstock G.M., Mardis E.R., et al. Evolutionary and biomedical insights from the rhesus macaque genome. Science 2007, 316(5822):222-234.
45. Goldman-Rakic P.S. Circuitry of primate prefrontal cortex and regulation of behavior by representational memory. Comprehensive physiology 2011, John Wiley & Sons, Inc.
46. Gotham A.M., Brown R.G., Marsden C.D. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 1988, 111(Pt 2):299-321.
47. Grandgeorge M., Bourreau Y., Alavi Z., Lemonnier E., Tordjman S., Deleau M., et al. Interest towards human, animal and object in children with autism spectrum disorders: An ethological approach at home. European Child and Adolescent Psychiatry 2015, 24(1):83-93.
48. Gustavsson A., Svensson M., Jacobi F., Allgulander C., Alonso J., Beghi E., et al. Cost of disorders of the brain in Europe 2010. European Neuropsychopharmacology 2011, 21(10):718-779.
49. Habbershon H.M., Ahmed S.Z., Cohen Y.E. Rhesus macaques recognize unique multimodal face-voice relations of familiar individuals and not of unfamiliar ones. Brain, Behavior and Evolution 2013, 81(4):219-225.
50. Hackam D.G. Translating animal research into clinical benefit. BMJ 2007, 334(7586):163-164.
51. Hackam D.G., Redelmeier D.A. Translation of research evidence from animals to humans. JAMA 2006, 296(14):1731-1732.
52. Hampel H., Buerger K., Zinkowski R., Teipel S.J., Goernitz A., Andreasen N., et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Archives of General Psychiatry 2004, 61(1):95-102.
53. Hauser R.A., Hubble J.P., Truong D.D. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003, 61(3):297-303.
54. Head E., Pop V., Sarsoza F., Kayed R., Beckett T.L., Studzinski C.M., et al. Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. Journal of Alzheimers Disease 2010, 20(2):637-646.
55. Herculano-Houzel S. The human brain in numbers: A linearly scaled-up primate brain. Frontiers in Human Neuroscience 2009, 3:31.
56. Herculano-Houzel S., Manger P.R., Kaas J.H. Brain scaling in mammalian evolution as a consequence of concerted and mosaic changes in numbers of neurons and average neuronal cell size. Frontiers Neuroanatomy 2014, 8:77.
57. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274(5284):99-102.
58. Hubel D.H., Wiesel T.N. Receptive fields of optic nerve fibres in the spider monkey. Journal of Physiology 1960, 154:572-580.
59. Ioannidis J.P. Why most discovered true associations are inflated. Epidemiology 2008, 19(5):640-648.
60. Ioannidis J.P. Extrapolating from animals to humans. Science Translational Medicine 2012, 4(151). 151ps115.
61. Jack C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132(Pt 5):1355-1365.
62. Janssen P.A.J. Screening tests and prediction from animals to man. Animal behaviour and drug action; A Ciba foundation symposium 1964, 264-268. J.A. Churchill Ltd., London. H. Steinberg, A.V.S. de Reuck, J. Knight (Eds.).
63. Janssen G., van Aken L., De Mey H., Witteman C., Egger J. Decline of executive function in a clinical population: Age, psychopathology, and test performance on the Cambridge Neuropsychological Test Automated Battery (CANTAB). Applied Neuropsychology Adult 2014, 21(3):210-219.
64. Kim E., Ku J., Kim J.-J., Lee H., Han K., Kim S.I., et al. Nonverbal social behaviors of patients with bipolar mania during interactions with virtual humans. The Journal of Nervous and Mental Disease 2009, 197(6):412-418.
65. Kohler E., Keysers C., Umilta M.A., Fogassi L., Gallese V., Rizzolatti G. Hearing sounds, understanding actions: Action representation in mirror neurons. Science 2002, 297(5582):846-848.
66. Lange K.W., Robbins T.W., Marsden C.D., James M., Owen A.M., Paul G.M. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berlin) 1992, 107(2-3):394-404.
67. Lees A.J., Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983, 106(Pt 2):257-270.
68. LeWitt P.A., Guttman M., Tetrud J.W., Tuite P.J., Mori A., Chaikin P., et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). Annals of Neurology 2008, 63(3):295-302.
69. Limousin P., Krack P., Pollak P., Benazzouz A., Ardouin C., Hoffmann D., et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. New England Journal of Medicine 1998, 339(16):1105-1111.
70. Liu R.T., Alloy L.B. Stress generation in depression: A systematic review of the empirical literature and recommendations for future study. Clinical Psychology Review 2010, 30(5):582-593.
71. Liu H., Chen Y., Niu Y., Zhang K., Kang Y., Ge W., et al. TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys. Cell Stem Cell 2014, 14(3):323-328.
72. Ljungberg T., Apicella P., Schultz W. Responses of monkey midbrain dopamine neurons during delayed alternation performance. Brain Research 1991, 567(2):337-341.
73. Macleod M.R., O'Collins T., Howells D.W., Donnan G.A. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 2004, 35(5):1203-1208.
74. Mantini D., Corbetta M., Romani G.L., Orban G.A., Vanduffel W. Evolutionarily novel functional networks in the human brain?. Journal of Neuroscience 2013, 33(8):3259-3275.
75. Markou A., Chiamulera C., Geyer M.A., Tricklebank M., Steckler T. Removing obstacles in neuroscience drug discovery: The future path for animal models. Neuropsychopharmacology 2009, 34(1):74-89.
76. Martic-Kehl M.I., Schibli R., Schubiger P.A. Can animal data predict human outcome? Problems and pitfalls of translational animal research. European Journal of Nuclear Medicine and Molecular Imaging 2012, 39(9):1492-1496.
77. Matthews R.A. Medical progress depends on animal models - Doesn't it?. Journal of the Royal Society of Medicine 2008, 101(2):95-98.
78. Matthews K., Christmas D., Swan J., Sorrell E. Animal models of depression: Navigating through the clinical fog. Neuroscience and Biobehavioral Reviews 2005, 29(4-5):503-513.
79. Meissner W., Prunier C., Guilloteau D., Chalon S., Gross C.E., Bezard E. Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. Molecular Neurobiology 2003, 28(3):209-218.
80. Michalak J., Troje N.F., Fischer J., Vollmar P., Heidenreich T., Schulte D. Embodiment of sadness and depression-gait patterns associated with dysphoric mood. Psychosomatic Medicine 2009, 71(5):580-587.
81. Moore T.L., Killiany R.J., Herndon J.G., Rosene D.L., Moss M.B. Executive system dysfunction occurs as early as middle-age in the rhesus monkey. Neurobiology of Aging 2006, 27(10):1484-1493.
82. Nagahara A.H., Bernot T., Tuszynski M.H. Age-related cognitive deficits in rhesus monkeys mirror human deficits on an automated test battery. Neurobiology of Aging 2010, 31(6):1020-1031.
83. Nederhof E., Schmidt M.V. Mismatch or cumulative stress: Toward an integrated hypothesis of programming effects. Physiology & Behavior 2012, 106(5):691-700.
84. Nelson E.E., Winslow J.T. Non-human primates: Model animals for developmental psychopathology. Neuropsychopharmacology 2009, 34(1):90-105.
85. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nature Neuroscience 2010, 13(10):1161-1169.
86. Niu Y., Shen B., Cui Y., Chen Y., Wang J., Wang L., et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 2014, 156(4):836-843.
87. Nutt D., Goodwin G. ECNP summit on the future of CNS drug research in Europe 2011: Report prepared for ECNP by David Nutt and Guy Goodwin. European Neuropsychopharmacology 2011, 21(7):495-499.
88. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 2003, 39(3):409-421.
89. Olesen J., Gustavsson A., Svensson M., Wittchen H.U., Jonsson B. The economic cost of brain disorders in Europe. European Journal of Neurology 2012, 19(1):155-162.
90. Olesen J., Leonardi M. The burden of brain diseases in Europe. European Journal of Neurology 2003, 10(5):471-477.
91. Overall K.L. Natural animal models of human psychiatric conditions: Assessment of mechanism and validity. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2000, 24(5):727-776.
92. Owen A.M., James M., Leigh P.N., Summers B.A., Marsden C.D., Quinn N.P., et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992, 115(Pt 6):1727-1751.
93. Pantelis C., Barnes T.R., Nelson H.E., Tanner S., Weatherley L., Owen A.M., et al. Frontal-striatal cognitive deficits in patients with chronic schizophrenia. Brain 1997, 120(Pt 10):1823-1843.
94. Parr L.A., Modi M., Siebert E., Young L.J. Intranasal oxytocin selectively attenuates rhesus monkeys' attention to negative facial expressions. Psychoneuroendocrinology 2013, 38(9):1748-1756.
95. Perel P., Roberts I., Sena E., Wheble P., Briscoe C., Sandercock P., et al. Comparison of treatment effects between animal experiments and clinical trials: Systematic review. BMJ 2007, 334(7586):197.
96. Peters A., Rosene D.L., Moss M.B., Kemper T.L., Abraham C.R., Tigges J., et al. Neurobiological bases of age-related cognitive decline in the rhesus monkey. Journal of Neuropathology and Experimental Neurology 1996, 55(8):861-874.
97. Price D.L., Martin L.J., Sisodia S.S., Wagster M.V., Koo E.H., Walker L.C., et al. Aged non-human primates: An animal model of age-associated neurodegenerative disease. Brain Pathology 1991, 1(4):287-296.
98. Prinz F., Schlange T., Asadullah K. Believe it or not: How much can we rely on published data on potential drug targets?. Nature Reviews Drug Discovery 2011, 10(9):712.
99. Prunier C., Bezard E., Montharu J., Mantzarides M., Besnard J.C., Baulieu J.L., et al. Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT. Neuroimage 2003, 19(3):810-816.
100. Punnett R.C. Mendelism in relation to disease. Proceedings of Royal Society of Medicine 1908, 1(Sect Epidemiol State Med):135-168.
101. Ramsden M., Kotilinek L., Forster C., Paulson J., McGowan E., SantaCruz K., et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). Journal of Neuroscience 2005, 25(46):10637-10647.
102. Recasens A., Dehay B., Bove J., Carballo-Carbajal I., Dovero S., Perez-Villalba A., et al. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Annals of Neurology 2014, 75(3):351-362.
103. Robbins T.W., James M., Owen A.M., Sahakian B.J., McInnes L., Rabbitt P. Cambridge neuropsychological test automated battery (CANTAB): A factor analytic study of a large sample of normal elderly volunteers. Dementia 1994, 5(5):266-281.
104. Robbins T.W., Semple J., Kumar R., Truman M.I., Shorter J., Ferraro A., et al. Effects of scopolamine on delayed-matching-to-sample and paired associates tests of visual memory and learning in human subjects: Comparison with diazepam and implications for dementia. Psychopharmacology (Berlin) 1997, 134(1):95-106.
105. Roelfsema P.R., Treue S. Basic neuroscience research with nonhuman primates: A small but indispensable component of biomedical research. Neuron 2014, 82(6):1200-1204.
106. Rose N. The human brain project: Social and ethical challenges. Neuron 2014, 82(6):1212-1215.
107. Russell W.M.S., Burch R.L. The principles of humane experimental technique 1959, Methuen, London.
108. Sabbagh J.J., Kinney J.W., Cummings J.L. Animal systems in the development of treatments for Alzheimer's disease: Challenges, methods, and implications. Neurobiology of Aging 2013, 34(1):169-183.
109. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309(5733):476-481.
110. Schmidt M.V. Animal models for depression and the mismatch hypothesis of disease. Psychoneuroendocrinology 2011, 36(3):330-338.
111. Schneider J.S. Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. Brain Research 1990, 534(1-2):25-36.
112. Schneider J.S., Pioli E.Y., Jianzhong Y., Li Q., Bezard E. Effects of memantine and galantamine on cognitive performance in aged rhesus macaques. Neurobiology of Aging 2013, 34(4):1126-1132.
113. Schneider J.S., Pioli E.Y., Jianzhong Y., Li Q., Bezard E. Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model. Movement Disorders 2013, 28(5):663-667.
114. Schneider J.S., Tinker J.P., Menzaghi F., Lloyd G.K. The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. Journal of Pharmacology and Experimental Therapeutics 2003, 306(1):401-406.
115. Schneider J.S., Tinker J.P., Van Velson M., Menzaghi F., Lloyd G.K. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. Journal of Pharmacology and Experimental Therapeutics 1999, 290(2):731-739.
116. Seay B., Hansen E., Harlow H.F. Mother-infant separation in monkeys. Journal of Child Psychology and Psychiatry 1962, 3(4):123-132.
117. Selkoe D.J., Bell D.S., Podlisny M.B., Price D.L., Cork L.C. Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science 1987, 235(4791):873-877.
118. Sena E., van der Worp H.B., Howells D., Macleod M. How can we improve the pre-clinical development of drugs for stroke?. Trends in Neurosciences 2007, 30(9):433-439.
119. Sereno M.I., Tootell R.B. From monkeys to humans: What do we now know about brain homologies?. Current Opinion in Neurobiology 2005, 15(2):135-144.
120. Sharpe M.H. Auditory attention in early Parkinson's disease: An impairment in focused attention. Neuropsychologia 1992, 30(1):101-106.
121. Shively C.A., Willard S.L. Behavioral and neurobiological characteristics of social stress versus depression in nonhuman primates. Experimental Neurology 2012, 233(1):87-94.
122. Suomi S.J. Early determinants of behaviour: Evidence from primate studies. British Medical Bulletin 1997, 53(1):170-184.
123. Suomi S.J., Eisele C.D., Grady S.A., Harlow H.F. Depressive behavior in adult monkeys following separation from family environment. Journal of Abnormal Psychology 1975, 84(5):576-578.
124. Taffe M.A., Davis S.A., Gutierrez T., Gold L.H. Ketamine impairs multiple cognitive domains in rhesus monkeys. Drug and Alcohol Dependence 2002, 68(2):175-187.
125. Taffe M.A., Weed M.R., Gold L.H. Scopolamine alters rhesus monkey performance on a novel neuropsychological test battery. Brain Research. Cognitive Brain Research 1999, 8(3):203-212.
126. Taffe M.A., Weed M.R., Gutierrez T., Davis S.A., Gold L.H. Modeling a task that is sensitive to dementia of the Alzheimer's type: Individual differences in acquisition of a visuo-spatial paired-associate learning task in rhesus monkeys. Behavioural Brain Research 2004, 149(2):123-133.
127. Thierry B. Unity in diversity: Lessons from macaque societies. Evolutionary Anthropology: Issues, News, and Reviews 2007, 16(6):224-238.
128. Thierry B., Iwaniuk A.N., Pellis S.M. The influence of phylogeny on the social behaviour of macaques. Ethology 2000, 106:713-728.
129. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282(5391):1145-1147.
130. Uchida S., Soshiroda K., Okita E., Kawai-Uchida M., Mori A., Jenner P., et al. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets. European Journal of Pharmacology 2015, 747:160-165.
131. van der Staay F.J. Animal models of behavioral dysfunctions: Basic concepts and classifications, and an evaluation strategy. Brain Research Reviews 2006, 52(1):131-159.
132. van der Worp H.B., de Haan P., Morrema E., Kalkman C.J. Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia. Journal of Neurology 2005, 252(9):1108-1114.
133. van der Worp H.B., Howells D.W., Sena E.S., Porritt M.J., Rewell S., O'Collins V., et al. Can animal models of disease reliably inform human studies?. PLoS Med 2010, 7(3):e1000245.
134. van der Worp H.B., Macleod M.R. Preclinical studies of human disease: Time to take methodological quality seriously. Journal of Molecular and Cellular Cardiology 2011, 51(4):449-450.
135. Vardigan J.D., Cannon C.E., Puri V., Dancho M., Koser A., Wittmann M., et al. Improved cognition without adverse effects: Novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey. Psychopharmacology (Berlin) 2014.
136. Wallis J.D. Cross-species studies of orbitofrontal cortex and value-based decision-making. Nature Neuroscience 2012, 15(1):13-19.
137. Webster S.J., Wilson C.A., Lee C.H., Mohler E.G., Terry A.V., Buccafusco J.J. The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys. British Journal of Pharmacology 2011, 164(3):970-978.
138. Weed M.R., Taffe M.A., Polis I., Roberts A.C., Robbins T.W., Koob G.F., et al. Performance norms for a rhesus monkey neuropsychological testing battery: Acquisition and long-term performance. Brain Research. Cognitive Brain Research 1999, 8(3):185-201.
139. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., Delon M.R. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982, 215(4537):1237-1239.
140. Willner P. The validity of animal models of depression. Psychopharmacology (Berlin) 1984, 83(1):1-16.
141. Wimo A., Winblad B., Jonsson L. The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dementia 2010, 6(2):98-103.
142. Yang S.H., Cheng P.H., Banta H., Piotrowska-Nitsche K., Yang J.J., Cheng E.C., et al. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 2008, 453(7197):921-924.
143. Yin M., Borton D.A., Komar J., Agha N., Lu Y., Li H., et al. Wireless neurosensor for full-spectrum electrophysiology recordings during free behavior. Neuron 2014, 84(6):1170-1182.
144. Zilka N., Korenova M., Kovacech B., Iqbal K., Novak M. CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy. Acta Neuropathologica 2010, 119(6):679-687.